Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

Downloaded from https://aidsinfo.nih.gov/guidelines on 1/30/2019

Visit the AIDSinfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
What’s New in the Guidelines

Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents document was published in an electronic format that could be easily updated as relevant changes in prevention and treatment recommendations occur.

The editors and subject matter experts are committed to timely changes in this document because so many health care providers, patients, and policy experts rely on this source for vital clinical information.

All changes are developed by the subject matter groups listed in the document (changes in group composition are also promptly posted). These changes are reviewed by the editors and by relevant outside reviewers before the document is altered. Major revisions within the last 6 months are as follows:

November 29, 2018

1. Human Papillomavirus Disease: The Panel updated the recommendation on HPV vaccination in females and males with HIV infection ages 13 to 26 years to the 9-valent HPV recombinant vaccine (0.5 ml at 0, 1 to 2, and 6 months) (AIII). For patients who have completed a vaccination series with the recombinant bivalent or quadrivalent vaccines, many experts would give an additional full series of the 9-valent recombinant vaccine (CIII).

November 13, 2018

1. Hepatitis B Virus Infection: The panel added information regarding the recently approved two-dose hepatitis B vaccine conjugated to a TLR9 agonist (Heplisav-B). Since there are no data on this vaccine in HIV-infected individuals, we present it as an option with a CIII recommendation. The panel added recommendations regarding considerations to prevent HBV reactivation during immunosuppressive therapy in patients with HBsAg-negative/anti-HBc positive disease: Starting tenofovir/emtricitabine backbone when possible with other options presented if this cannot be given.

2. Progressive Multifocal Leukoencephalopathy/JC Virus Infection: The section was updated to reflect current information about the value of plasma PCR and to include updated references on failed therapies.

May 29, 2018

1. Human Papillomavirus Disease: The panel added a recommendation for ASC-US with negative reflex HPV: For ASC-US Pap test, if reflex HPV testing is negative, a repeat Pap test in 6-12 months or repeat co-testing in 12 months is recommended. For any result ≥ ASC-US on repeat cytology, referral to colposcopy is recommended (AII).

2. Introduction: The section was updated to reflect current information about the panel’s processes, policies, and membership.